Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.58 |
| ▸ | PTPN7 | P35236 | 6/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 6/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.42 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10299813 | 1.00 | KIF11 (0.58) | KIF11PTPN7DUSP3NR3C2AR | |
| SCHEMBL29875866 | 1.00 | KIF11 (0.58) | KIF11PTPN7DUSP3NR3C2AR | |
| SCHEMBL3637053 | 0.84 | NR3C2 (0.49) | KIF11PTPN7DUSP3NR3C2AR | |
| SCHEMBL17414234 | 0.83 | KIF11 (0.44) | KIF11PTPN7DUSP3NR3C2AR | |
| SCHEMBL92971 | 0.83 | KIF11 (0.73) | KIF11CYP4F2CYP4A11P2RX7 | |
| SCHEMBL1994099 | 0.83 | KIF11 (0.56) | KIF11ARCYP4F2CYP4A11 | |
| SCHEMBL30368288 | 0.83 | KIF11 (0.56) | KIF11ARCYP4F2CYP4A11 | |
| SCHEMBL10662203 | 0.83 | PTPN7 (0.47) | KIF11PTPN7DUSP3NR3C2AR | |
| SCHEMBL26074532 | 0.82 | CYP4F2 (0.46) | KIF11PTPN7DUSP3ARCYP4F2 | |
| SCHEMBL81056 | 0.81 | NR3C2 (0.47) | KIF11PTPN7DUSP3NR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3547414-B1 | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG ENERGY SOLUTION LTD (KR) | 2023-09-13 | — | — | EP | claimed |
| EP-3664213-B1 | ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME | LG ENERGY SOLUTION LTD (KR) | 2023-09-13 | — | — | EP | claimed |
| US-11495824-B2 | Electrolyte for lithium metal battery and lithium metal battery comprising same | LG ENERGY SOLUTION, LTD. (KR) | 2022-11-08 | — | — | US | claimed |
| CN-110192294-B | Lithium electrode and lithium secondary battery comprising same | 株式会社LG新能源 | 2022-09-20 | — | — | CN | claimed |
| CN-111033864-B | Electrolyte for lithium metal battery and lithium metal battery comprising same | 株式会社LG新能源 | 2022-08-12 | — | — | CN | claimed |
| EP-3664213-A2 | ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME | LG Chem, Ltd. (KR) | 2020-06-10 | — | — | EP | claimed |
| US-20190319272-A1 | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG CHEM, LTD. (KR) | 2019-10-17 | — | — | US | claimed |
| EP-3547414-A2 | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG Chem, Ltd. (KR) | 2019-10-02 | — | — | EP | claimed |
| US-7122536-B2 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC. (US) | 2006-10-17 | — | — | US | claimed |
| US-7015230-B1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-03-21 | — | — | US | claimed |
| WO-2001077079-A2 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-10-18 | — | — | WO | claimed |
| WO-2001077097-A2 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-10-18 | — | — | WO | claimed |
| WO-2001068605-A1 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED BENZENES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-09-20 | — | — | WO | claimed |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2001-08-30 | — | — | US | claimed |
| EP-1115695-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(N+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1115694-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC (TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018724-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018723-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | KIF11 4755/4885PTPN7 3654/4885DUSP3 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.